Is deafness mutation screening required in cystic fibrosis patients?

Aminoglycosides are widely used in cystic fibrosis management. The m.1555A>G mutation predisposes to aminoglycoside ototoxicity. It may cause later onset hearing loss in the absence of aminoglycosides use and gradual hearing loss may be an inevitable consequence of the mutation. Given that aminoglycoside therapy forms the backbone of IV protocols in CF, this article recommends screening for this mutation to allow informed decision-making prior to aminoglycoside administration, to avoid preventable deafness.

Source: Paediatric Respiratory Reviews - June 13, 2016 Category: Respiratory Medicine Authors: Rania Abusamra, Donna McShane Source Type: research